Theranostic Pipeline Leveraging the Power of Targeted Alpha-Particles
We are developing a pipeline of radiotherapies designed to deliver powerful alpha radiation directly to cancer cells utilizing specialized targeting peptides. We are also developing complementary diagnostics that utilize the same targeting peptide to provide the opportunity to understand which patients may respond to therapy.
| Program | Indication | Discovery | Human Clinical Imaging | First in Human Therapy | Phase 1/2 | Phase 3 |
|---|---|---|---|---|---|---|
| VMT-𝛼-NET | Neuroendocrine cancer |
|
||||
| Pheochromocytomas, paragangliomas |
|
|||||
| Small cell lung cancer |
|
|||||
| VMT-01 | Melanoma (MCIR) |
|
||||
| VMT-02 (PET agent) | Melanoma (imaging of MC1R) |
|
||||
| Program 3 (Novel peptide) | Multiple solid tumors |
|
||||
| Program 4 (Novel small molecule) | Prostate |
|
||||
| Program 5 (Novel peptide) | Prostate, Breast |
|
||||
| Other Programs | Solid and hematological tumors |
|
||||
VMT01 is in development for the treatment and diagnosis of metastatic melanoma. Through the use of a specialized peptide, VMT01 is designed to target the melanocortin 1 receptor (MC1R) on tumor cells. VMT01 is currently being evaluated in a Phase 1 imaging study being conducted at the Mayo Clinic Rochester. Following the results of the imaging trial, the Company plans to initiate a Phase 1/2a therapy study.
VMT-𝛼-NET is in development for the treatment and diagnosis of somatostatin receptor subtype 2 (SSTR2). VMT-𝛼-NET is expected to enter a Phase 1 imaging study in Q3, 2021 that will be conducted at the University of Iowa Hospitals and Clinics.